Alteplase

Alteplase Struktur
105857-23-6
CAS-Nr.
105857-23-6
Englisch Name:
Alteplase
Synonyma:
D02837;Alteplase;Activase (tn);Alteplase (usp/inn);Alteplase USP/EP/BP;Sparsentan Impurity 44;ALTEPLASE(105857-23-6);Alteplase (genetical recombination);Alteplase (genetical recombination) (jan);PlasMinogen activator (huMan tissue-type protein Moiety) (9CI)
CBNumber:
CB61401954
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

Alteplase Eigenschaften

Sicherheit

Alteplase Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Alteplase is a recombinant single-chain tissue plasminogen activator useful in the management of thrombosis in acute myocardial infarct. It reportedly causes no allergic reactions but requires intravenous infusion due to a short half-life. Alteplase is the only agent on the U.S. market indicated for the reduction of incidence of congestive heart failure following a heart attack.

Verwenden

Tissue-type plasminogen activator; fibrinolytic.

Allgemeine Beschreibung

Alteplase (Activase) is a tissue plasminogenactivator (t-PA) produced by rDNA technology. It is a single-chain glycoprotein protease consisting of 527 aminoacid residues. Native t-PA is isolated from a melanoma cellline. The single-chain molecule is susceptible to enzymaticdigestion to a two-chain molecule, in which the two chainsremain linked with a disulfide bond. Both forms of the nativet-PA are equipotent in fibrinolytic (and plasminogenactivating)properties. It is an extrinsic plasminogen activatorassociated with vascular endothelial tissue, whichpreferentially activates plasminogen bound to fibrin. Thefibrinolytic action of alteplase (t-PA) is confined to thrombi,with minimal systemic activation of plasminogen. It is producedcommercially by rDNA methods by inserting the alteplasegene (acquired from human melanoma cells) intoovarian cells of the Chinese hamster, serving as host cells.The melanoma-derived alteplase is immunologically andchemically identical with the uterine form. Alteplase is indicatedfor the intravenous management of acute myocardialinfarction.

Mechanism of action

As a main endogenic promoter of fibrinolysis, t-PA binds with fibrin and, like urokinase, breaks Arg-560–Val-561 peptide bond in the fibrin-binded plasminogen molecule, thus turning it into an active plasmin molecule that breaks apart fibrin clots. Its action is localized in thrombotic regions, and thus the likelihood of systemic fibrinolysis originating during its use is much lower than that which can originate while using streptokinase and urokinase.

Clinical Use

Alteplase (tPA) is a serine protease with a low affinity for free plasminogen but a very high affinity for the plasminogen bound to fibrin in a thrombus (fibrin-specific agent). Both streptokinase and urokinase lack this specificity (i.e., are nonspecific) and act on free plasminogen, inducing a generalized thrombolytic state. Alteplase also has a greater specificity for older clots compared with newer clots relative to streptokinase and urokinase. Alteplase was originally isolated from cultures of human melanoma cells but is now produced commercially using recombinant DNA technology.

Nebenwirkungen

Alteplase is unmodified human tPA, whereas reteplase is human tPA that has had several specific amino acid sequences removed. At low doses, alteplase is quite selective for degrading fibrin without concomitant lysis of other proteins, such as fibrinogen. At the higher doses currently used therapeutically, however, alteplase activates free plasminogen to some extent and, therefore, can cause hemorrhage. Many of the therapeutic indications for the other thrombolytic agents also are indications for alteplase (i.e., myocardial infarction, massive pulmonary embolism, and acute ischemic stroke).

Alteplase Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Alteplase Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 16)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21700 55
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715
admin@nexconn.com China 7836 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29831 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58
Hangzhou Huarong Pharm Co., Ltd.
571-86758373 +8613588754946
sales@huarongpharm.com CHINA 3149 58
PT CHEM GROUP LIMITED
+86-85511178 +86-85511178
peter68@ptchemgroup.com China 35453 58
GIHI CHEMICALS CO.,LIMITED
+8618058761490
info@gihichemicals.com China 50001 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2127 70
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12338 58
Copyright 2019 © ChemicalBook. All rights reserved